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Purpose: To assess whether rheumatoid arthritis (RA) is associated with a greater risk of 
adverse events following total knee replacement (TKR) and total hip replacement (THR) than 
osteoarthritis (OA).
Patients and methods: Individuals with a diagnosis of RA or OA were identified using primary 
care records. TKR and THR following diagnosis were identified using linked hospital records. 
Myocardial infarction (MI), prosthetic joint infection (PJI), venous thromboembolism (VTE), 
and death were identified within 90 days following surgery, and revision procedures over 10 
years following surgery. The impact of RA compared to OA on the risk for these adverse events 
was assessed using Cox proportional hazard models. Univariable models, with diagnosis as the 
only explanatory variable, and multivariable models, with age, gender, and year of surgery first 
added and then a measure of other comorbidities also included, were estimated.
Results: In all 20,763 individuals, with 10,260 TKR and 10,961 THR, were included in the 
analysis. Compared to those with OA, individuals with a diagnosis of RA had a greater incidence 
of MI over 90 days following TKR (OA: 0.28%, RA: 0.75%) and revision over 10 years following 
THR (OA: 5.55%, RA: 8.68%). Both of these differences were statistically significant with, for 
example, hazard ratios of 3.54 (1.44 to 8.73) for MI and 1.61 (1.06 to 2.46) for revision after 
controlling for age, gender, year of surgery, and other comorbidities.
Conclusion: These findings suggest that, compared to individuals with OA, those with RA 
have an increased short-term risk of MI following TKR. While risk of MI remains below 1%, 
this does underline the importance of the management of cardiovascular risk factors for those 
with RA. RA was also associated with an increased long-term risk of revision following THR, 
which strengthens the argument for investing in therapies which may prevent the need for joint 
replacement. 
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Introduction
Total knee replacement (TKR) and total hip replacement (THR) typically result in 
substantial improvements in pain, function, and overall quality-of-life.1,2 As with any 
surgical procedure, however, there is a risk of adverse events. Potential perioperative 
complications for joint replacement include myocardial infarction (MI), venous throm-
boembolism (VTE), prosthetic joint infection (PJI), and even mortality. In addition, 
there is a long-term risk of revision following surgery, in which implant components 
are removed, added or exchanged. 
Risks of adverse events following TKR and THR have mostly been estimated for 
individuals with osteoarthritis (OA), with OA being the most common indication for 
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surgery. A sizeable minority of patients undergoing TKR and 
THR, however, have inflammatory arthropathies, of which 
the most common is rheumatoid arthritis (RA). Outside of 
surgery, RA has been linked with increased risks for a range 
of health conditions. It is well-established that individuals 
with RA have an increased risk of cardiovascular disease 
(CVD), in particular ischemic heart disease, and related 
mortality compared to the general population.3–5 In addi-
tion, while the evidence is less conclusive, RA has also been 
linked with an increased general risk of VTE6 and a greater 
susceptibility for serious infections, due to both the disease 
itself and immunosuppressive treatments.7 
While it is plausible that individuals with RA would also 
be at a higher risk of adverse events following joint replace-
ment compared to those with OA, this relationship is not well 
understood. In this study, therefore, we assessed whether RA 
is associated with a greater risk of adverse events following 
TKR and THR compared to OA.
Ethical approval




Routinely-collected data from the English National Health 
Service (NHS) informed the analysis. Primary care practices 
within the Clinical Practice Research Datalink (CPRD) were 
linked to inpatient hospital records, provided by Hospital 
Episode Statistics Admitted Patient Care (HES APC), and 
mortality data, from the Office for National Statistics (ONS). 
HES APC data were extracted from 1997, the earliest year 
available, to 2014. CPRD data were extracted from 1995 to 
2014 while ONS records were extracted from 1997 to 2014 
to match HES APC.
Study participants
Individuals were identified separately for procedures relat-
ing to the knee and hip. For TKR, individuals with an inci-
dent (newly recorded) diagnosis of RA or knee OA were 
identified on the basis of clinical codes in CPRD. The first 
occurrence of a TKR following the index diagnosis was then 
identified using HES APC. A similar process was used for 
inclusion in the analysis of THR, with individuals required 
to have an incident diagnosis of hip OA or RA followed by 
the procedure. 
Where an individual had a diagnosis of both RA and OA, 
it was not possible to determine which of their diagnoses 
drove the decision for joint replacement. As RA is a systemic 
inflammatory disease it was taken as the index diagnosis for 
the analyses. 
Bilateral TKRs or THRs, where both the left and right 
joint were replaced  simultaneously or staged, were excluded 
from the analysis due to the difficultly in establishing an 
appropriate time window and attributing adverse events as 
side of surgery was not consistently recorded. As the cohorts 
were established independently, the same individual could 
contribute both a TKR and a THR in the analysis. 
In addition to identifying diagnoses, CPRD records 
also provided information on an individual’s gender and 
year of birth. HES APC records contained information on 
 individuals’ primary procedure (TKR or THR), with the date 
of the procedure used to identify the year of surgery and, 
given an individual’s year of birth recorded in CPRD, age at 
surgery. Diagnostic codes recorded for the primary procedure 
in HES APC were used to calculate an individual’s Royal 
College of Surgeons (RCS) Charlson comorbidity score.8 
Adverse events
Adverse events over 90 days (VTE, PJI, MI, and death) and 
10 years (revision) following TKR and THR were identified 
using HES APC records. VTE and MI were identified on 
the basis of the primary diagnoses codes from the hospital 
episode (a period of hospital care under one consultant) in 
which the joint replacement occurred or any subsequent 
episode within the specified follow-up. PJI was identified 
by the corresponding ICD code as the primary diagnosis of 
hospital episodes and  a concurrent or subsequent operation 
code either debridement, antibiotics, irrigation, and retention 
of the prosthesis or revision within a year of the diagnosis.9 
Mortality records were based on data from the ONS. 
Only incident adverse events were included in the analy-
sis. If an individual had an event of interest recorded prior 
to their TKR or THR, they were excluded from the analysis 
of that event.
Statistical methods
The characteristics of individuals with an index diagnosis 
of OA or RA were compared in terms of standardized mean 
difference (SMD). An SMD of <0.1 indicates that there is 
minimal difference in the mean of a covariate between the 
two groups.10 
The number of adverse events over 90 days (VTE, PJI, MI 
or death) and 10 years (revision) following surgery and the 
corresponding cumulative incidence, which gives the prob-
ability of experiencing the event within the time period under 




RA and the risk of adverse events following joint replacement
consideration before the occurrence of the competing risk of 
death (if mortality was not the adverse event in question),11 
were estimated. These were compared for individuals with 
an index diagnosis of OA and those with a diagnosis of RA.
Cox proportional hazards regression models were then 
used to assess the association between RA and observed 
adverse events over 90 days (VTE, PJI, MI or death) and 
10 years (revision) following surgery, relative to OA. Aside 
from mortality itself, other adverse events had mortality as 
a competing risk. Cause-specific hazard ratios (HRs) were 
therefore estimated, along with 95% CIs, for non-fatal events 
and overall HRs for mortality. For each outcome, follow-up 
ended at the earliest of: a second TKR or THR, the end of 
data linkage with CPRD or date of data extraction, death, or 
transfer out. Models were only estimated if there were more 
than five events in the RA group.
Univariable models were first estimated with only diagno-
sis of RA or OA included. Subsequently, age, gender, and year 
of surgery were also included as explanatory factors. Finally, 
to control for the effect of other comorbidities on the risk of 
adverse events, the RCS Charlson score was also included 
(with codes for RA excluded to avoid double counting its 
effect). Further, the RCS Charlson score was dichotomized 
as 0 and 1+ due to relatively small numbers of patients with 
multiple comorbidities. Proportionality was considered 
through a visual assessment of Schoenfeld residuals.
Data analysis was undertaken in R 3.3.1,12 with dplyr13 
used for data manipulation, survival14 for fitting regression 
models and ggplot215 for producing cumulative incidence 
plots. 
Sensitivity analyses
A sensitivity analysis was undertaken where adverse events 
were considered over the year following joint replacement, 
rather than within only the first 90 days. The analysis was 
also re-run excluding individuals who had both a diagnosis 
of RA and OA recorded. 
Results
Study participants
In all 20,763 individuals informed the analysis with 458 con-
tributing to both the TKR and THR analyses. In total, 10,260 
TKR (9,409 knee OA and 851 RA) and 10,961 THR (10,322 
hip OA and 639 RA) were included. A flow chart summariz-
ing inclusion into the study is provided in the Supplementary 
materials. Individuals’ characteristics are detailed in Table 
1. The number and cumulative incidence of adverse events 
following TKR and THR are detailed by diagnosis in Table 
2. As there were fewer than five events for those with RA, 
regression models were not estimated for PJI following TKR 
and THR and MI following THR. The cumulative incidences 
of revision over 10 years following TKR and THR are shown 
in Figure 1.
Adverse events following TKR
There was a higher incidence of MI over the 90 days follow-
ing TKR among individuals with RA compared to those with 
OA (RA: 0.75%, OA: 0.28%), (Table 2). This difference was 
significant in regression models, such as after adjustment for 
age, gender, and year of surgery (HR: 3.57 [95% CI: 1.45 
to 8.80]), (Table 3).
Year of surgery being closer to the end of follow-up 
was associated with a significantly reduced risk of death 
(HR: 0.90 [0.84 to 0.97]). Higher age at surgery and male 
gender were also associated with significantly increased 
risk of 90-day MI (HRs: 1.11 [1.06 to 1.16] and 3.88 [1.76 
to 8.55], respectively, from full multivariable regressions). 
Higher age at surgery and comorbidity (RCS Charlson score 
of 1+) were associated with an increased risk of 90-day post-
operative mortality (HRs: 1.09 [1.05 to 1.14] and 2.65 [1.45 
to 4.82] from full multivariable regressions). Older age at 
surgery was associated with a reduced risk of revision over 
the 10 years following TKR (HR: 0.96 [0.94 to 0.97]), while 
male gender was associated with an increased risk (HR: 
1.32 [1.04 to 1.68], from full multivariable regressions). 
Fully specified models are provided in the Supplementary 
materials.
Adverse events following THR
There was a higher incidence of revision over the 10 years 
following THR among individuals with RA compared to 
those with OA (RA: 8.68%, OA: 5.55%), (Table 2). This 
difference was significant in regression models, such as after 
adjustment for age, gender, and year of surgery (HR: 1.64 
[95% CI: 1.08 to 2.50]), (Table 3).
Year of surgery being closer to the end of follow-up was 
associated with a significantly reduced risk of VTE and death 
(HRs: 0.91 [0.87 to 0.95] and 0.89 [0.84 to 0.94], respec-
tively). Higher age at surgery, male gender, and comorbidity 
(RCS Charlson score of 1+) were each associated with a sig-
nificantly increased risk of 90-day mortality following THR 
(HRs: 1.12 [1.09 to 1.15], 1.81 [1.12 to 2.94], and 2.52 [1.53 
to 4.15] from full multivariable regressions, respectively). 
Older age at surgery was associated with a reduced risk of 
revision over the 10 years following THR (HR: 0.99 [0.98 
to 1.00] from the fully specified regression). 






Assessing adverse events over 1 year rather than 90 days led 
to broadly similar findings (details provided in Supplementary 
materials). As in the primary analysis, a diagnosis of RA was 
associated with a significantly increased risk of MI following 
TKR (HR: 3.02 [1.68 to 5.41] from the model adjusted for age, 
Table 1 Characteristics of study participants
THR TKR
OA RA SMD OA RA SMD
n 9,409 851 10,322 639
Age (median [IQR]) 71.0 [64.0, 77.0] 69.0 [61.5, 75.0] 0.21 70.0 [62.0, 77.0] 70.0 [62.0, 76.0] 0.06
Gender: female (n [%]) 5240 [55.7] 594 [69.8] 0.29 5957 [57.7] 479 [75.0] 0.37
Year of surgery (median [IQR]) 2009 [2006, 2011] 2008 [2005, 2011] 0.19 2008 [2005, 2011] 2008 [2005, 2011] 0.03
Diagnoses recorded in HES APC
Myocardial infarction (n [%]) 127 [1.3] 11 [1.3] 0.01 131 [1.3] 9 [1.4] 0.01
Congestive cardiac failure (n [%]) 88 [0.9] 8 [0.9] <0.01 127 [1.2] 10 [1.6] 0.03
Peripheral vascular disease (n [%]) 93 [1.0] 8 [0.9] <0.01 95 [0.9] 7 [1.1] 0.02
Cerebrovascular disease (n [%]) 52 [0.6] 2 [0.2] 0.05 52 [0.5] 4 [0.6] 0.02
Dementia (n [%]) 21 [0.2] 4 [0.5] 0.04 32 [0.3] 5 [0.8] 0.06
Chronic pulmonary disease (n [%]) 986 [10.5] 105 [12.3] 0.06 918 [8.9] 80 [12.5] 0.12
Rheumatological disease* (n [%]) 75 [0.8] 24 [2.8] 0.15 105 [1.0] 19 [3.0] 0.14
Liver disease (n [%]) 19 [0.2] 1 [0.1] 0.02 20 [0.2] 2 [0.3] 0.02
Diabetes mellitus (n [%]) 933 [9.9] 58 [6.8] 0.11 708 [6.9] 47 [7.4] 0.02
Hemiplegia or paraplegia (n [%]) 18 [0.2] 0 [0.0] 0.06 15 [0.1] 2 [0.3] 0.04
Renal disease (n [%]) 183 [1.9] 19 [2.2] 0.02 222 [2.2] 13 [2.0] 0.01
Any malignancy (n [%]) 74 [0.8] 4 [0.5] 0.04 92 [0.9] 5 [0.8] 0.01
Metastatic solid tumor (n [%]) 6 [0.1] 0 [0.0] 0.04 8 [0.1] 2 [0.3] 0.05
AIDS HIV infection (n [%]) 0 0 0 1 [0.0] 0 [0.0] 0.01
RCS Charlson* (n [%]) 0.06 0.14
0 7161 [76.1] 643 [75.6] 8203 [79.5] 474 [74.2]
1 1876 [19.9] 174 [20.4] 1777 [17.2] 131 [20.5]
2 320 [3.4] 32 [3.8] 282 [2.7] 29 [4.5]
3+ 52 [0.6] 2 [0.2] 60 [0.6] 5 [0.8]
Note: *Codes for RA were omitted from the calculation of the rheumatological disease category and for the overall RCS Charlson score. 
Abbreviations: TKR, total knee replacement; THR, total hip replacement; OA, osteoarthritis; RA, rheumatoid arthritis; SMD, standardized mean difference; IQR, inter-
quartile range; n, number; HES APC, Hospital Episode Statistics Admitted Patient Care; RCS, Royal College of Surgeons. 
Table 2 Adverse events following TKR and THR
OA RA
Number of events Cumulative incidence (%) Number of events Cumulative incidence (%)
TKR
90-day
VTE 79 0.86 (0.67 to 1.05) 5 0.61 (0.07 to 1.14)
PJI 17 0.19 (0.10 to 0.27) 2 0.23 (0.00 to 0.56)
MI 24 0.28 (0.17 to 0.39) 6 0.75 (0.15 to 1.34)
Death 43 0.46 (0.33 to 0.60) 3 0.36 (0.00 to 0.76)
10-year
Revision 248 5.73 (4.63 to 6.82) 18 5.07 (1.04 to 8.94)
THR
90-day
VTE 106 1.05 (0.85 to 1.25) 5 0.79 (0.10 to 1.48)
PJI 12 0.12 (0.05 to 0.18) 2 0.32 (0.00 to 0.76)
MI 31 0.32 (0.21 to 0.44) 1 0.16 (0.00 to 0.48)
Death 61 0.60 (0.45 to 0.75) 7 1.11 (0.29 to 1.92)
10-year
Revision 255 5.55 (4.68 to 6.41) 24 8.68 (4.27 to 12.88)
Note: Number and cumulative incidence of VTE, PJI, MI, and death following TKR and THR split by index diagnosis of OA or RA.
Abbreviations: TKR, total knee replacement; THR, total hip replacement; OA, osteoarthritis; RA, rheumatoid arthritis; VTE, venous thromboembolism; PJI, prosthetic 
joint infection; MI, myocardial infarction.




RA and the risk of adverse events following joint replacement
gender, and year of surgery). In addition, RA was also associated 
with significantly increased risk of death after THR over the 
year following surgery (HR: 2.60 [1.62 to 4.17] from the model 
adjusted for age, gender, and year of surgery). The results were 
broadly similar after excluding individuals with both a diagnosis 
of RA and OA, with RA still associated with an increased risk 
of revision (HR: 1.72 [1.07 to 2.78] from the unadjusted model). 
However, while the cumulative incidence of MI following TKR 
was still higher for RA, there were too few events to run the 
regression model to assess the effect of other explanatory factors 
(see Supplementary materials for further details).
Discussion
Key results
Individuals with a diagnosis of RA had a greater incidence of 
MI over 90 days following TKR compared to those with OA 
(OA: 0.28%, RA: 0.75%), with this difference being statisti-
cally significant after controlling for age, gender, and year 
of surgery (HR: 3.57 [1.45 to 8.80]). Patients with RA were 
also more likely to undergo a revision surgery over the 10 
years following THR than individuals with OA (OA: 5.55%, 
RA: 8.68%), with this difference also statistically significant 
after controlling for age, gender, and year of surgery (HR: 
1.64 [1.08 to 2.50]). 
Study findings in context
In our study, a prior diagnosis of RA was not associated with 
significant differences in the risk for VTE over 90 days or 1 
year following TKR or THR. Previous studies have also found 
patients with RA not to be at a significantly increased risk 
of VTE following joint replacement compared to those with 
OA.16,17 While estimates were not significant in this study, 
Figure 1 Cumulative incidence of revision. 
Notes: Observed cumulative incidence of revision following (A) total knee replacement (TKR) and (B) total hip replacement (THR), stratified by diagnosis of rheumatoid 



















































younger age at surgery has previously been associated with 
a significantly lower risk of VTE following THR.17
In this study, there were insufficient cases of PJI to assess 
whether there was a significant difference between those with 
OA and RA. However, previous research has found RA to 
be associated with an increased risk of PJI compared to OA. 
Over the year following surgery, for example, RA was found 
to be associated with sub-hazard ratio (SHR) of 1.46 (1.13-
1.88).18 This increased risk could be caused by a reduced 
immune system response due to RA or by the immunosup-
pressive treatments being taken.19 Younger age at surgery and 
additional comorbidities have previously been associated 
with a significantly lower risk of infection following THR.17
A prior diagnosis of RA was associated with a signifi-
cantly increased 90-day risk of MI following TKR compared 
to OA in our data. There were too few cases of MI, however, 
to estimate whether there was a difference following THR. 
Despite the high cardiovascular risk profile of RA patients, 
and the known peak in risk of MI following joint replace-
ment,20 few studies have assessed whether those with RA 
are at higher risk of cardiovascular events following joint 
replacement compared to those with OA. One study, however, 
previously found RA to be associated with an increased risk 
of cardiovascular death within 6 weeks of joint replacement 
compared to those without a diagnosis of OA, (odds ratio 
[OR] of 1.50 [0.96–2.33]).21 In line with the findings from 
this study, older age and comorbidities have also previously 
been found to be associated with significantly higher risks 
of cardiac events following both TKR and THR.22 
In this analysis, we found no significant increase in risk of 
mortality over 90 days following either TKR or THR for those 
with RA. RA, however, was associated with significantly 
higher mortality over 1 year following THR. RA has been 
found to be associated with an increased risk of mortality over 
90 days following THR (OR: 1.88 [1.17 to 3.03]),17 over 6 
weeks (OR: 1.85 [1.09 to 3.13]),21 and 1 year (HR: 1.25 [1.01 
to 1.55])18 following joint replacement in general. A diagno-
sis of RA is also associated with increased risk of mortality 
compared to OA in general.23 Consequently, the increased 
risk observed following surgery for RA is not necessarily 
attributable to the receipt of surgery but may reflect under-
lying differences in baseline risk of mortality. Consistent 
with the findings from this study, older age, comorbidities, 
and male gender have been found to be associated with an 
increased risk of 90- and 45-day mortality following THR 
and TKR, respectively.24,25 
We found RA, compared to OA, to be associated with 
a significantly increased 10-year risk of revision following 
THR. RA has previously been associated with an increased 
risk of hip dislocation following THR.26,27 Hip dislocation, 
one of the most common reasons for early revision following 
THR, may explain the increased risk of revision estimated 
Table 3 Association between RA and risk of post-operative adverse events
Estimated effect of RA compared to OA, hazard ratio  (95% CI)
Unadjusted model Multivariable model with age, 
gender, and year of surgery 
included
Multivariable model with age, 




VTE 0.70 (0.29 to 1.74) 0.71 (0.29 to 1.76) 0.70 (0.28 to 1.74)
PJI – – –
MI 2.69 (1.10 to 6.59) 3.57 (1.45 to 8.80) 3.54 (1.44 to 8.73)
Death 0.77 (0.24 to 2.47) 0.85 (0.26 to 2.74) 0.82 (0.25 to 2.64)
10-year
Revision 0.79 (0.49 to 1.28) 0.71 (0.43 to 1.14) 0.71 (0.44 to 1.15)
THR
90-day
VTE  0.77 (0.31 to 1.89) 0.74 (0.30 to 1.83) 0.74 (0.30 to 1.81)
PJI – – –
MI – – –
Death 1.85 (0.85 to 4.05) 2.31 (1.05 to 5.07) 2.17 (0.98 to 4.77)
10-year
Revision 1.63 (1.07 to 2.48) 1.64 (1.08 to 2.50) 1.61 (1.06 to 2.46)
Notes: Hazard ratios associated with diagnosis of RA relative to OA for VTE, MI, and death following TKR and THR. There were too few PJIs following TKR and THR and 
MI following THR for meaningful regression analysis to be undertaken. Full model specifications are reported in the Supplementary materials. *Codes for RA were omitted 
from the calculation of the RCS Charlson score and the score was dichotomized as 0 and 1+.
Abbreviations: TKR, total knee replacement; THR, total hip replacement; OA, osteoarthritis; RA, rheumatoid arthritis; VTE, venous thromboembolism; PJI, prosthetic joint 
infection; MI, myocardial infarction; RCS, Royal College of Surgeons.




RA and the risk of adverse events following joint replacement
in this study. Findings from previous studies, however, are 
mixed. Studies have found patients with RA not to be at a 
significantly increased long-term risk of revision following 
THR,26,28 a reduced risk of revision for reasons other than 
infection (SHR: 0.71 [0.57 to 0.89]),18 and also an increased 
risk of revision for infection following TKR (relative risk: 1.6 
[1.06 to 2.38]).29 The effect of RA therefore seems to vary 
depending on the reason for revision. Moreover, the mixed 
findings regarding long-term risks of revision have likely 
been influenced by study design and, in particular, whether 
the competing risk of mortality was accounted for. Aside 
from a recent study,18 the competing risk of mortality has not 
been taken into account in most previous analyses. In line 
with previous studies, younger age at surgery was associated 
with an increased risk of revision following both TKR and 
THR.30 Male gender was associated with an increased risk 
of revision following TKR in this study and has previously 
been associated with an increased risk following both TKR 
and THR in the UK.31
Strengths and limitations of this study
This study was informed by routinely collected data. The 
primary concern with such data is typically the accuracy of 
coding, given that data collection is not undertaken primarily 
for research purposes. Where possible, therefore, validated 
codes were used in this study. However, while the codes used 
to identify diagnoses of RA in CPRD have previously been 
validated,32 the OA codes have not. It can be expected that 
although the specificity of OA diagnosis will have been high, 
given that individuals went on to have joint replacement, the 
sensitivity may have been less so. Consequently, there is a 
concern as to how representative those with OA in this study 
are of the population in general. 
Despite the potential limitations, the key strength of this 
study was the use of linked primary care and hospital data. 
This allowed for the identification of diagnoses using primary 
care data and procedures and subsequent adverse events from 
hospital records. In addition, the use of routinely collected 
data has allowed for the inclusion of a large “real-world” 
study population, sufficient to test for important differences 
in risks of rare adverse events.
Study implications
Individuals with RA are at increased risk of MI over 90 days 
following knee replacement compared to those with OA. As 
with the general increased risk of cardiovascular events for 
those with RA, this is likely due to both the nature of the 
disease itself and medications used in its treatment. While in 
absolute terms the observed incidence of MI remained <1%, 
this finding underlines the importance of the management of 
cardiovascular risk factors for those with RA, for example 
through the use of anti-TNF and methotrexate treatments, 
particularly prior to TKR.4
Compared to OA, RA has also been found in this study 
to be associated with an increased risk of revision over the 
10 years following THR. With a cumulative incidence of 
over 8% for those with RA, compared to 5% for those with 
OA, the additional revisions represent a significant cost 
to providers and burden of ill-health for individuals. This 
will only strengthen the argument for investing in available 
therapies which may delay or entirely prevent the need for 
joint replacement for those with RA.
Data access and data sharing
CPRD data with HES linkage were provided under a license 
that does not permit sharing. Data are obtainable from CPRD 
subject to a full application.
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